Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates
about
Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism.Heterologous exchanges of the glycoprotein and the matrix protein in a Novirhabdovirus.The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity.Nonsegmented negative-strand viruses as vaccine vectors.Roles of the fusion and hemagglutinin-neuraminidase proteins in replication, tropism, and pathogenicity of avian paramyxoviruses.Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.Patterns of epistasis in RNA viruses: a review of the evidence from vaccine design.The M, F and HN genes of genotype VIId Newcastle disease virus are associated with the severe pathological changes in the spleen of chickens.Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium.A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animalsChimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles.Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins.Altered interaction of the matrix protein with the cytoplasmic tail of hemagglutinin modulates measles virus growth by affecting virus assembly and cell-cell fusion.
P2860
Q33840469-36D47FE1-6E2F-4DE2-941E-61846DE31611Q33911962-06E3B07A-721D-4DB1-AEE1-F81DA5B3B8F1Q34332631-D7E8ED4E-1061-4246-AD0A-BE87CB3DCB42Q34515872-5DE2D18A-F5EE-4E52-8AC0-9E533BF17F61Q35139219-38D0B28D-50E7-4BF8-AC3A-4FE4B0320E3AQ35192881-F3A9716A-4F24-45FE-9CD5-8C136254BC77Q35285887-4FC87CCE-70DE-4A6B-BA82-0A4DB34D5750Q35593849-35387D09-41E3-4453-8A63-0E5512AD9FC8Q36023225-8EE90AD5-5681-4DD5-93F9-20D3ED9FD9D8Q36312804-15D7A877-1EE7-4C4F-B259-790D5313FA78Q36844471-0060F3E1-391D-424A-B80D-0DB6C38DBED3Q37113787-7BFA2B07-4EAD-44C9-B63E-7EE3D0F96A16Q37247965-D042D6E0-6C85-488F-A6DC-C2C338285F0EQ37348134-2D78C807-C629-4435-ACFE-3D3EF185115FQ37713874-E018F01C-0C4F-4FD7-822D-808796F1565FQ41890251-C8C1E212-4A4C-46DC-BF0F-E5846E1C776AQ42013767-02FAD98A-03DF-463F-84A6-D3A39B005D75
P2860
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Replacement of the ectodomains ...... nuated PIV2 vaccine candidates
@ast
Replacement of the ectodomains ...... nuated PIV2 vaccine candidates
@en
Replacement of the ectodomains ...... nuated PIV2 vaccine candidates
@nl
type
label
Replacement of the ectodomains ...... nuated PIV2 vaccine candidates
@ast
Replacement of the ectodomains ...... nuated PIV2 vaccine candidates
@en
Replacement of the ectodomains ...... nuated PIV2 vaccine candidates
@nl
prefLabel
Replacement of the ectodomains ...... nuated PIV2 vaccine candidates
@ast
Replacement of the ectodomains ...... nuated PIV2 vaccine candidates
@en
Replacement of the ectodomains ...... nuated PIV2 vaccine candidates
@nl
P2093
P2860
P921
P1433
P1476
Replacement of the ectodomains ...... nuated PIV2 vaccine candidates
@en
P2093
B R Murphy
M H Skiadopoulos
P L Collins
P2860
P304
P356
10.1128/JVI.74.14.6448-6458.2000
P577
2000-07-01T00:00:00Z